NewsRoom Articles - Page 31 of 214

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer’s Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer’s Disease, and INM-901-treated Alzheimer’s Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

FridayAug 23, 2024 10:00 am

How Health Technology Could Improve Customer Experience

Any business in the healthcare sector seeking to improve customer experience, popularly known as CX, may benefit from using health technology. Data from Forrester Research shows that 6% of brands that took part in the 2023 U.S. Customer Experience rankings saw increases in quality of customer experiences. 8x8’s chief technology officer, Bryan Martin, believes this may be because brands aren’t investing in processes and tools to enhance customer experiences. To boost customer experiences, healthcare organizations can concentrate on: Automation and Artificial Intelligence The use of manual processes is frustrating, not only for organizations but also to patients. Automation of an…

ThursdayAug 22, 2024 1:33 pm

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Two Phase 2 independently conducted clinical trials showed significant improvement in key biomarkers among ALS patients who were administered CNM-Au8 Biomarker and efficacy data was submitted to the Food and Drug Administration for a granted Type C meeting request, with the company targeting an accelerated approval pathway CEO Rob Etherington expressed optimism about CNM-Au8's potential as a new ALS treatment, and voiced hope that ALS patients will benefit sooner rather than later Clene recently presented its latest updates and findings at the Canaccord Genuity 44th Annual Growth Conference Clene (NASDAQ: CLNN), a late clinical-stage biopharmaceutical company focused on improving mitochondrial…

WednesdayAug 21, 2024 10:00 am

Scientists Find Way to Boost Natural Killer Cells Targeting Pediatric Brain Cancer

Natural killer cells are white blood cells that eliminate cancer or other infected cells in the human body. Now a new study has looked into these cells’ ability to eliminate a certain type of cancer known as malignant rhabdoid tumor. This aggressive and rare type of brain cancer starts developing in a child’s kidneys, soft tissues or other organs. It mainly affects young children and babies. In some instances, natural killer cells can be overpowered by the cancer cells. Scientists at Florida State University may have found a way to enhance natural killer cells that target this pediatric cancer. The…

TuesdayAug 20, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

Annovis Bio’s lead drug candidate buntanetap has the potential to significantly improve the quality of life for early Alzheimer’s patients In a short-term Phase 2/3 study, buntanetap has been shown to work three times better than the standard of care in the market The company plans further clinical trials to validate the efficacy and safety of buntanetap in treating both Parkinson’s and Alzheimer’s diseases Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases, presented significant data and findings of its Phase 2/3 Alzheimer’s study of lead drug candidate buntanetap at the Alzheimer’s Association…

MondayAug 19, 2024 1:30 pm

UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis

Multiple sclerosis is an autoimmune condition that affects an individual’s brain and spinal cord, causing symptoms that include difficulty walking or problems with one’s vision or balance. The condition’s mechanism of action involves using an individual’s immune system to attack the myelin, a protein and fatty substance that protects and surrounds nerve fibers. By damaging myelin, nerves aren’t able to carry electrical impulses from and to the brain. This damage also allows scar tissue known as sclerosis to form. This chronic disease of the central nervous system may, in some cases, lead to severe disability. Now, researchers at Contineum Therapeutics…

FridayAug 16, 2024 10:00 am

Enrollment for Medicare Advantage Differs Sharply in California Counties

In America, Medicare Advantage is increasing in popularity among beneficiaries of Medicare. Insurers under this version of Medicare offer lower premiums, with dental and vision coverage added on. Jointly, more than 50% of eligible recipients of Medicare are on private plans. However, a recent report from KFF determined that there were huge differences between enrollment in Medicare Advantage in the northern and southern counties of California. Data from the Centers for Medicare & Medicaid Services shows that market penetration for Medicare Advantage was considerably lower in northern counties in comparison to southern counties. The state of California differs from other…

WednesdayAug 14, 2024 10:00 am

Studies Show Protein, Reelin, Protects Brain Against Alzheimer’s, Aging

Researchers conducting separate studies published last year all determined that reelin, a protein that helps maintain memory and thinking in the brain, may also protect this important organ from diseases of aging such as Alzheimer’s. The researchers also found that if levels of reelin decrease, the vulnerability of neurons increases. Professor Li-Huei Tsai of MIT stated that increasing evidence had shown that reelin acted as a protector of the brain. Tsai is also the director of the Picower Institute for Learning and Memory. The studies have inspired efforts to develop medications that help reelin function better or boost its levels…

WednesdayAug 14, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement

Annovis Bio’s lead compound, buntanetap, shows significant enhanced cognitive benefits when combined with GLP-1 agonist dulaglutide in a mouse model Buntanetap targets neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases GLP-1 agonists, typically used for diabetes, weight loss, and heart conditions, have shown potential in addressing neuroinflammation and neurodegeneration The combination treatment results were compelling: While buntanetap alone restored cognitive function to 100% and dulaglutide alone to 80%, the combination restored and also enhanced cognitive function beyond levels seen in healthy controls Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company, announced new preclinical data demonstrating lead compound buntanetap’s potential…

MondayAug 12, 2024 10:30 am

Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions

Clene has conducted five Phase 2 clinical trials, three with long-term extensions, and three expanded access programs (with additional studies ongoing) to evaluate the safety and efficacy of CNM-Au8 The global ALS treatment market is poised for growth, driven by an aging population and limited current treatment options CNM-Au8 works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health, and is at a deficit in neurodegenerative diseases Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc. is a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases,…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

How Health Technology Could Improve Customer Experience

Clene Inc.’s (NASDAQ: CLNN) CNM-Au8(R) Affects Key Biomarkers and Long-term Survival in ALS Trials

Scientists Find Way to Boost Natural Killer Cells Targeting Pediatric Brain Cancer

Annovis Bio Inc. (NYSE: ANVS) CEO Discusses Findings of Buntanetap Phase 2/3 Alzheimer’s Study on the Bell2Bell Podcast

UCSF Team Tests New Drug That Could Reverse Multiple Sclerosis

Enrollment for Medicare Advantage Differs Sharply in California Counties

Studies Show Protein, Reelin, Protects Brain Against Alzheimer’s, Aging

Annovis Bio Inc. (NYSE: ANVS) Lead Compound Shows Synergistic Cognitive Enhancement

Clene Inc.’s (NASDAQ: CLNN) Makes Significant Strides in Developing its Lead Agent, CNM-Au8(R), to Address Neurodegenerative Conditions

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search